Newsletter Reports On Stocks To Watch And New Valuation Check After Research In Motion Earnings Release newsletter reports on four companies with compelling stock values.

Sarasota, FL (PRWEB) October 8, 2007 -- The alert newsletter is reporting today, October 8, 2007, that it has completed its valuation research on Research In Motion (Nasdaq: RIMM) after the company reported earnings after the bell on October 4, 2007. Kevin Evans, a spokesperson, stated, "Based on the company's upward guidance for the 3rd quarter, we believe the stock is fairly valued and the story is still a compelling one ... especially with the company pushing into emerging markets. We alerted the stock a month ago at which time it was trading at a little over one time its estimated 5 year annual growth rate. The stock price has jumped up since then, but with upward revisions after the earnings report, the stock could still be trading a little over one time its annual growth rate."

In the past few days, the newsletter has also performed valuation research on and alerted ShengdaTech Inc. (Nasdaq: SDTH), Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), and Vital Images, Inc. (Nasdaq: VTAL). The newsletter reports alerting ShengdaTech Inc. to its subscribers based on the company's fast growth and extremely low PEG ratio. The newsletter reports that the stock was trading at just 11.78 times next year's earnings estimates and with the company expected to grow at an estimated 42% a year for the next five years, the stock has a PEG ratio of .28, which means the company is growing at a little over 1/4 its annual growth rate. "We particularly like that the Chinese company supplies many of the products that China will need for growth in that country," stated the newsletter spokesperson.

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) was alerted by the newsletter at $13.51 a share after Nastech Pharm announced in early October the initiation of Phase 2 clinical trials for PYY3-36 nasal spray to treat obesity and announced in late September the start of a Phase 2 clinical trial evaluating the company's rapid-acting Insulin Nasal Spray in approx 20 patients with type 2 diabetes.

Vital Images, Inc. (Nasdaq: VTAL) was alerted by the newsletter at $20.03 a share due to reports that colon scans might possibly be an equal and/or better replacement to a colonoscopy at a fraction of the cost. The newsletter alerted the stock based on valuation considering the stock was trading near its 52 week low and the possibility that health insurance companies might accept the scans as an alternative to a colonoscopy.

Since 1998 the online newsletter has been known for offering 30 days free and alerting its subscribers to the markets biggest winners. The website can be reached at for more information about their outstanding stock alert program and one month free trial. is not a registered broker/dealer and the newsletter's stock alerts are not a solicitation or recommendation to buy, sell or hold securities., its employees or affiliates are not compensated by the companies highlighted. The material in this release is intended to be strictly informational and is the sole opinion of These opinions may change at any time without notice. Although the information is believed to be correct, the accuracy or completeness of the information is not guaranteed or warranted. disclaims any and all liability as to the completeness, accuracy or possible omissions of the information contained herein. Due to risk involved, investment or stock trading decisions should be discussed with a registered broker or financial adviser. is not liable for any investment decisions made by its subscribers, trial subscribers or readers.

# # #